The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
[acetyl methyl tetramethyl tetralin co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in decreased expression of CIDEA mRNA
[acetyl methyl tetramethyl tetralin co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in increased expression of CIDEC mRNA; [quinoxyfen co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in increased expression of CIDEC mRNA
[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of Pantothenic Acid; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of Pantothenic Acid]; Dexamethasone inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of Pantothenic Acid]; huang-lien-chieh-tu-tang inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of Pantothenic Acid]
IDH2 protein mutant form results in increased abundance of Pantothenic Acid Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Pantothenic Acid]
[acetyl methyl tetramethyl tetralin co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in decreased expression of CIDEA mRNA; [acetyl methyl tetramethyl tetralin co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in decreased expression of SDHA protein; [acetyl methyl tetramethyl tetralin co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in increased expression of CIDEC mRNA; [quinoxyfen co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in decreased expression of SDHA protein; [quinoxyfen co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in increased expression of CIDEC mRNA
[Glycerol co-treated with Succinic Acid co-treated with Glucose-6-Phosphate co-treated with Pantothenic Acid co-treated with Niacinamide] results in increased expression of NR4A1 mRNA
[acetyl methyl tetramethyl tetralin co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in decreased expression of SDHA protein; [quinoxyfen co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in decreased expression of SDHA protein
SLC5A6 results in increased transport of Pantothenic Acid Sodium affects the reaction [SLC5A6 results in increased transport of Pantothenic Acid] Thioctic Acid inhibits the reaction [SLC5A6 results in increased transport of Pantothenic Acid]
[acetyl methyl tetramethyl tetralin co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in decreased expression of CIDEA mRNA; [acetyl methyl tetramethyl tetralin co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in decreased expression of SDHA protein; [acetyl methyl tetramethyl tetralin co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in increased expression of CIDEC mRNA; [quinoxyfen co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in decreased expression of SDHA protein; [quinoxyfen co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in increased expression of CIDEC mRNA
Galantamine results in decreased activity of ACHE protein Galantamine inhibits the reaction [Scopolamine results in increased activity of ACHE protein] Galantamine binds to and results in decreased activity of ACHE protein; Galantamine inhibits the reaction [asoxime chloride inhibits the reaction [Sarin results in decreased activity of ACHE protein]]; Galantamine inhibits the reaction [Obidoxime Chloride metabolite results in decreased activity of ACHE protein]; Galantamine promotes the reaction [Obidoxime Chloride inhibits the reaction [Sarin results in decreased activity of ACHE protein]]
Galantamine inhibits the reaction [APP protein modified form results in decreased expression of CHRNA7 protein]; methyllycaconitine inhibits the reaction [Galantamine inhibits the reaction [APP protein modified form results in decreased expression of CHRNA7 protein]]
Galantamine binds to [CHRNA4 protein binds to CHRNB2 protein] Galantamine inhibits the reaction [Acetylcholine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]]
Galantamine inhibits the reaction [APP protein modified form results in decreased expression of CHRNA7 protein]; methyllycaconitine inhibits the reaction [Galantamine inhibits the reaction [APP protein modified form results in decreased expression of CHRNA7 protein]]
Galantamine binds to [CHRNA4 protein binds to CHRNB2 protein] Galantamine inhibits the reaction [Acetylcholine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]]
Neostigmine results in increased activity of PYGL protein modified form Phentolamine inhibits the reaction [Neostigmine results in increased activity of PYGL protein modified form]
Physostigmine inhibits the reaction [AADAC protein results in decreased acetylation of Rifabutin]; Physostigmine inhibits the reaction [AADAC protein results in decreased acetylation of Rifampin]; Physostigmine inhibits the reaction [AADAC protein results in decreased acetylation of rifapentine]
Physostigmine results in decreased activity of ACHE protein Physostigmine affects the expression of ACHE mRNA [Corticosterone co-treated with Physostigmine] results in decreased activity of ACHE protein; Physostigmine inhibits the reaction [Streptozocin results in increased activity of ACHE protein] [Physostigmine co-treated with Dichlorvos] results in decreased activity of ACHE protein; [Physostigmine inhibits the reaction [Soman results in decreased activity of ACHE protein]] which results in decreased carbamoylation of ACHE protein; ALB protein affects the reaction [Physostigmine results in decreased activity of ACHE protein]; Physostigmine inhibits the reaction [Soman results in decreased activity of ACHE protein] asoxime chloride affects the reaction [Physostigmine results in decreased activity of ACHE protein]; asoxime chloride promotes the reaction [Physostigmine inhibits the reaction [Soman results in decreased activity of ACHE protein]]; Physostigmine affects the expression of and affects the activity of ACHE protein; Physostigmine affects the reaction [Sarin affects the expression of ACHE mRNA]; Physostigmine affects the reaction [Sarin affects the expression of and affects the activity of ACHE protein]; Physostigmine inhibits the reaction [Soman results in decreased activity of ACHE protein] Physostigmine results in increased expression of ACHE protein
Physostigmine binds to [CHRNA4 protein binds to CHRNB2 protein] Physostigmine binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]; Physostigmine inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Physostigmine promotes the reaction [Acetylcholine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]]; Physostigmine results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]
Physostigmine binds to [CHRNA4 protein binds to CHRNB2 protein] Physostigmine binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]; Physostigmine inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Physostigmine promotes the reaction [Acetylcholine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]]; Physostigmine results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]
Physostigmine inhibits the reaction [Scopolamine promotes the reaction [SK&F 82958 results in increased expression of FOS mRNA]]; Physostigmine inhibits the reaction [SK&F 82958 results in increased expression of FOS mRNA]
[1-((4-fluorobenzoylamino)ethyl)-4-(7-methoxy-1-naphthyl)piperazine hydrochloride binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to Physostigmine; [8-Hydroxy-2-(di-n-propylamino)tetralin binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to Physostigmine; tertatolol inhibits the reaction [[1-((4-fluorobenzoylamino)ethyl)-4-(7-methoxy-1-naphthyl)piperazine hydrochloride binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to Physostigmine]; tertatolol inhibits the reaction [[8-Hydroxy-2-(di-n-propylamino)tetralin binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to Physostigmine]
Physostigmine inhibits the reaction [Scopolamine promotes the reaction [SK&F 82958 results in increased expression of JUN mRNA]]; Physostigmine inhibits the reaction [SK&F 82958 results in increased expression of JUN mRNA]
browse the term
